{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:50:10Z","timestamp":1791859810585,"version":"4.3.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,4,9]],"date-time":"2014-04-09T00:00:00Z","timestamp":1397001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s40263-014-0158-2","type":"journal-article","created":{"date-parts":[[2014,4,8]],"date-time":"2014-04-08T11:35:05Z","timestamp":1396956905000},"page":"571-581","source":"Crossref","is-referenced-by-count":103,"title":["PPAR-\u03b3 Agonism as a Modulator of Mood: Proof-of-Concept for Pioglitazone in Bipolar Depression"],"prefix":"10.1007","volume":"28","author":[{"given":"David E.","family":"Kemp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Schinagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Ganocy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faramarz","family":"Ismail-Beigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,9]]},"reference":[{"key":"158_CR1","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1001\/jama.299.23.2751","volume":"299","author":"SH Golden","year":"2008","unstructured":"Golden SH, Lazo M, Carnethon M, Bertoni AG, Schreiner PJ, Diez Roux AV, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA. 2008;299:2751\u20139.","journal-title":"JAMA"},{"key":"158_CR2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4088\/JCP.v69n0202","volume":"69","author":"H Koponen","year":"2008","unstructured":"Koponen H, Jokelainen J, Keinanen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Metabolic syndrome predisposes to depressive symptoms: a population-based 7-year follow-up study. J Clin Psychiatry. 2008;69:178\u201382.","journal-title":"J Clin Psychiatry"},{"key":"158_CR3","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2337\/dc11-2055","volume":"35","author":"A Pan","year":"2012","unstructured":"Pan A, Keum N, Okereke OI, Sun Q, Kivimaki M, Rubin RR, et al. Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies. Diabetes Care. 2012;35:1171\u201380.","journal-title":"Diabetes Care"},{"key":"158_CR4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4088\/JCP.08m04743blu","volume":"71","author":"N Vogelzangs","year":"2010","unstructured":"Vogelzangs N, Kritchevsky SB, Beekman AT, Brenes GA, Newman AB, Satterfield S. Obesity and onset of significant depressive symptoms: results from a prospective community-based cohort study of older men and women. J Clin Psychiatry. 2010;71:391\u20139.","journal-title":"J Clin Psychiatry"},{"key":"158_CR5","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/sj.mp.4001838","volume":"11","author":"M Timonen","year":"2006","unstructured":"Timonen M, Rajala U, Jokelainen J, Keinanen-Kiukaanniemi S, Meyer-Rochow VB, Rasanen P. Depressive symptoms and insulin resistance in young adult males: results from the Northern Finland 1966 birth cohort. Mol Psychiatry. 2006;11:929\u201333.","journal-title":"Mol Psychiatry"},{"key":"158_CR6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/PSY.0b013e318157ad2e","volume":"69","author":"M Timonen","year":"2007","unstructured":"Timonen M, Salmenkaita I, Jokelainen J, Laakso M, H\u00e4rk\u00f6nen P, Koskela P. Insulin resistance and depressive symptoms in young adult males: findings from Finnish military conscripts. Psychosom Med. 2007;69:723\u20138.","journal-title":"Psychosom Med"},{"key":"158_CR7","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1399-5618.2010.00823.x","volume":"12","author":"DE Kemp","year":"2010","unstructured":"Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JRC. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine\/metabolic system and treatment outcome. Bipolar Disord. 2010;12:404\u201313.","journal-title":"Bipolar Disord"},{"key":"158_CR8","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1176\/appi.ajp.2008.08081195","volume":"166","author":"DE Kemp","year":"2009","unstructured":"Kemp DE, Ismail-Beigi F, Calabrese JR. Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry. 2009;166:619.","journal-title":"Am J Psychiatry"},{"key":"158_CR9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3928\/00485713-20120507-05","volume":"42","author":"DE Kemp","year":"2012","unstructured":"Kemp DE, Fan J. Cardiometabolic health in bipolar disorder. Psychiatr Ann. 2012;42:179\u201383.","journal-title":"Psychiatr Ann"},{"key":"158_CR10","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nm.2349","volume":"17","author":"KK Ryan","year":"2011","unstructured":"Ryan KK, Li B, Grayson BE, Matter EK, Woods SC, Seeley RJ. A role for central nervous system PPAR-gamma in the regulation of energy balance. Nat Med. 2011;17:623\u20136.","journal-title":"Nat Med"},{"key":"158_CR11","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/npp.2011.205","volume":"37","author":"E Haroon","year":"2012","unstructured":"Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37:137\u201362.","journal-title":"Neuropsychopharmacology"},{"key":"158_CR12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/mp.2009.116","volume":"15","author":"CL Raison","year":"2010","unstructured":"Raison CL, Dantzer R, Kelley KW, Lawson MA, Woolwine BJ, Vogt G. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry. 2010;15:393\u2013403.","journal-title":"Mol Psychiatry"},{"key":"158_CR13","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1073\/pnas.0708092105","volume":"105","author":"JW Koo","year":"2008","unstructured":"Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA. 2008;105:751\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"158_CR14","doi-asserted-by":"crossref","first-page":"e8817","DOI":"10.1371\/journal.pone.0008817","volume":"5","author":"R Kleemann","year":"2010","unstructured":"Kleemann R, van Erk M, Verschuren L, van den Hoek AM, Koek M, Wielinga PY. Time-resolved and tissue-specific systems analysis of the pathogenesis of insulin resistance. PloS One. 2010;5:e8817.","journal-title":"PloS One"},{"key":"158_CR15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archpsyc.62.12.1322","volume":"62","author":"LL Judd","year":"2005","unstructured":"Judd LL, Akiskal HS, Schettler PJ, Endicott J, Leon AC, Solomon DA. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005;62:1322\u201330.","journal-title":"Arch Gen Psychiatry"},{"key":"158_CR16","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1677\/joe.0.1690453","volume":"169","author":"P Delerive","year":"2001","unstructured":"Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169:453\u20139.","journal-title":"J Endocrinol"},{"key":"158_CR17","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/j.1582-4934.2011.01318.x","volume":"15","author":"D Bosco","year":"2011","unstructured":"Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer\u2019s disease pathogenesis. J Cell Mol Med. 2011;15:1807\u201321.","journal-title":"J Cell Mol Med"},{"key":"158_CR18","first-page":"171","volume":"231","author":"JK Morris","year":"2011","unstructured":"Morris JK, Bomhoff GL, Gorres BK, Davis VA, Kim J, Lee PP. Insulin resistance impairs nigrostriatal dopamine function. ExpNeurol. 2011;231:171\u201380.","journal-title":"ExpNeurol"},{"key":"158_CR19","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1523\/JNEUROSCI.3779-10.2011","volume":"31","author":"AN Schoffelmeer","year":"2011","unstructured":"Schoffelmeer AN, Drukarch B, De Vries TJ, Hogenboom F, Schetters D, Pattij T. Insulin modulates cocaine-sensitive monoamine transporter function and impulsive behavior. J Neurosci. 2011;31:1284\u201391.","journal-title":"J Neurosci"},{"key":"158_CR20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.tins.2007.02.002","volume":"30","author":"S Lovestone","year":"2007","unstructured":"Lovestone S, Killick R, Di Forti M, Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007;30:142\u20139.","journal-title":"Trends Neurosci"},{"key":"158_CR21","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00023210-200822060-00001","volume":"22","author":"RS McIntyre","year":"2008","unstructured":"McIntyre RS, Vagic D, Swartz SA, Soczynska JK, Woldeyohannes HO, Voruganti LP, Konarski JZ. Insulin, insulin-like growth factors and incretins: neural homeostatic regulators and treatment opportunities. CNS Drugs. 2008;22:443\u201353.","journal-title":"CNS Drugs"},{"key":"158_CR22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/FBP.0b013e328331b9bf","volume":"20","author":"AA Eissa Ahmed","year":"2009","unstructured":"Eissa Ahmed AA, Al-Rasheed NM. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol. 2009;20:635\u201342.","journal-title":"Behav Pharmacol"},{"key":"158_CR23","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.bbr.2011.06.011","volume":"224","author":"MS Sadaghiani","year":"2011","unstructured":"Sadaghiani MS, Javadi-Paydar M, Gharedaghi MH, Fard YY, Dehpour AR. Antidepressant-like effect of pioglitazone in the forced swimming test in mice: the role of PPAR-gamma receptor and nitric oxide pathway. Behav Brain Res. 2011;224:336\u201343.","journal-title":"Behav Brain Res"},{"key":"158_CR24","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jad.2011.06.033","volume":"136","author":"DE Kemp","year":"2012","unstructured":"Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S, et al. Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord. 2012;136:1164\u201373.","journal-title":"J Affect Disord"},{"key":"158_CR25","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","volume":"59","author":"LL Judd","year":"2002","unstructured":"Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"158_CR26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","volume":"162","author":"JR Calabrese","year":"2005","unstructured":"Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351\u201360.","journal-title":"Am J Psychiatry"},{"key":"158_CR27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.31887\/DCNS.2008.10.2\/dekemp","volume":"10","author":"DE Kemp","year":"2008","unstructured":"Kemp DE, Muzina DJ, McIntyre RS, Calabrese JR. Bipolar depression: trial-based insights to guide patient care. Dialogues Clin Neurosci. 2008;10:181\u201392.","journal-title":"Dialogues Clin Neurosci"},{"key":"158_CR28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","volume":"60","author":"M Tohen","year":"2003","unstructured":"Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079\u201388.","journal-title":"Arch Gen Psychiatry"},{"key":"158_CR29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:160\u20138.","journal-title":"Am J Psychiatry"},{"key":"158_CR30","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","volume":"171","author":"A Loebel","year":"2014","unstructured":"Loebel A, Cucchiaro J, Silva R, Kroger H, Xu J, Calabrese JR. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171:169\u201377.","journal-title":"Am J Psychiatry"},{"key":"158_CR31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/YCO.0b013e3283413505","volume":"24","author":"J Chen","year":"2011","unstructured":"Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011;24:10\u20137.","journal-title":"Curr Opin Psychiatry"},{"key":"158_CR32","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/npp.2012.58","volume":"37","author":"K Sepanjnia","year":"2012","unstructured":"Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S. Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology. 2012;37:2093\u2013100.","journal-title":"Neuropsychopharmacology"},{"key":"158_CR33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/35154","volume":"391","author":"C Jiang","year":"1998","unstructured":"Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82\u20136.","journal-title":"Nature"},{"issue":"Suppl 20","key":"158_CR34","first-page":"22","volume":"59","author":"DV Sheehan","year":"2008","unstructured":"Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 2008;59(Suppl 20):22\u201333 (quiz 4-57).","journal-title":"J Clin Psychiatry"},{"key":"158_CR35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1017\/S0033291703001107","volume":"34","author":"MH Trivedi","year":"2004","unstructured":"Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34:73\u201382.","journal-title":"Psychol Med"},{"key":"158_CR36","doi-asserted-by":"crossref","unstructured":"Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.","DOI":"10.1001\/jama.285.19.2486"},{"key":"158_CR37","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/da.1033","volume":"13","author":"MK Shear","year":"2001","unstructured":"Shear MK, Vander Bilt J, Rucci P, Endicott J, Lydiard B, Otto MW, et al. Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A). Depress Anxiety. 2001;13:166\u201378.","journal-title":"Depress Anxiety"},{"key":"158_CR38","volume-title":"ECDEU assessment manual for psychopharmacology, revised","author":"W Guy","year":"1976","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville: National Institute of Mental Health; 1976."},{"key":"158_CR39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/BF00788510","volume":"27","author":"AC Leon","year":"1992","unstructured":"Leon AC, Shear MK, Portera L, Klerman GL. Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol. 1992;27:78\u201382.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"158_CR40","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","volume":"22","author":"M Matsuda","year":"1999","unstructured":"Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462\u201370.","journal-title":"Diabetes Care"},{"key":"158_CR41","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139.","journal-title":"Diabetologia"},{"key":"158_CR42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","volume":"67","author":"N Diazgranados","year":"2010","unstructured":"Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010;67:793\u2013802.","journal-title":"Arch Gen Psychiatry"},{"key":"158_CR43","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1176\/appi.ajp.163.2.210","volume":"163","author":"AA Nierenberg","year":"2006","unstructured":"Nierenberg AA, Ostacher MJ, Calabrese JR, Ketter TA, Marangell LB, Miklowitz DJ. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006;163:210\u20136.","journal-title":"Am J Psychiatry"},{"key":"158_CR44","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4088\/JCP.v63n0210","volume":"63","author":"TA Ketter","year":"2002","unstructured":"Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry. 2002;63:146\u201351.","journal-title":"J Clin Psychiatry"},{"key":"158_CR45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0278-5846(02)00255-5","volume":"26","author":"F Benedetti","year":"2002","unstructured":"Benedetti F, Lucca A, Brambilla F, Colombo C, Smeraldi E. Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1167\u201370.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"158_CR46","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.pnpbp.2009.03.020","volume":"33","author":"R Yoshimura","year":"2009","unstructured":"Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:722\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"158_CR47","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/mp.2012.125","volume":"18","author":"CD Rethorst","year":"2013","unstructured":"Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry. 2013;18:1119\u201324.","journal-title":"Mol Psychiatry"},{"key":"158_CR48","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.4088\/JCP.09m05314blu","volume":"71","author":"G Cizza","year":"2010","unstructured":"Cizza G, Nguyen VT, Eskandari F, Duan Z, Wright EC, Reynolds JC, et al. Low 24-hour adiponectin and high nocturnal leptin concentrations in a case-control study of community-dwelling premenopausal women with major depressive disorder: the Premenopausal, Osteopenia\/Osteoporosis, Women, Alendronate, Depression (POWER) study. J Clin Psychiatry. 2010;71:1079\u201387.","journal-title":"J Clin Psychiatry"},{"key":"158_CR49","doi-asserted-by":"crossref","first-page":"12248","DOI":"10.1073\/pnas.1202835109","volume":"109","author":"J Liu","year":"2012","unstructured":"Liu J, Guo M, Zhang D, Cheng SY, Liu M, Ding J, et al. Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity. Proc Natl Acad Sci USA. 2012;109:12248\u201353.","journal-title":"Proc Natl Acad Sci USA"},{"key":"158_CR50","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.2337\/diabetes.51.10.2968","volume":"51","author":"JG Yu","year":"2002","unstructured":"Yu JG, Javorschi S, Hevener AL, Kruszynska YT, Norman RA, Sinha M, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968\u201374.","journal-title":"Diabetes"},{"key":"158_CR51","doi-asserted-by":"crossref","first-page":"376","DOI":"10.2337\/diacare.25.2.376","volume":"25","author":"WS Yang","year":"2002","unstructured":"Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25:376\u201380.","journal-title":"Diabetes Care"},{"key":"158_CR52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jpsychires.2011.11.010","volume":"46","author":"IG Barbosa","year":"2012","unstructured":"Barbosa IG, Rocha NP, de Miranda AS, Magalh\u00e3es PV, Huguet RB, de Souza LP, et al. Increased levels of adipokines in bipolar disorder. J Psychiatr Res. 2012;46:389\u201393.","journal-title":"J Psychiatr Res"},{"key":"158_CR53","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","volume":"375","author":"S Kaptoge","year":"2010","unstructured":"Emerging Risk Factors C, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132\u201340.","journal-title":"Lancet"},{"key":"158_CR54","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","volume":"366","author":"JA Dormandy","year":"2005","unstructured":"Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspectivepioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279\u201389.","journal-title":"Lancet"},{"key":"158_CR55","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","volume":"9","author":"P Shah","year":"2010","unstructured":"Shah P, Mudaliar S. Pioglitazone: side effect and safety profile. Expert Opin Drug Saf. 2010;9:347\u201354.","journal-title":"Expert Opin Drug Saf"},{"key":"158_CR56","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/npp.2011.106","volume":"37","author":"LS Brady","year":"2012","unstructured":"Brady LS, Insel TR. Translating discoveries into medicine: psychiatric drug development in 2011. Neuropsychopharmacology. 2012;37:281\u20133.","journal-title":"Neuropsychopharmacology"},{"key":"158_CR57","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2337\/diab.43.9.1114","volume":"43","author":"MF Saad","year":"1994","unstructured":"Saad MF, Anderson RL, Laws A, Watanabe RM, Kades WW, Chen YD, et al. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes. 1994;43:1114\u201321.","journal-title":"Diabetes"},{"key":"158_CR58","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4088\/JCP.v69n1207","volume":"69","author":"SB Fleet-Michaliszyn","year":"2008","unstructured":"Fleet-Michaliszyn SB, Soreca I, Otto AD, Jakicic JM, Fagiolini A, Kupfer DJ, et al. A prospective observational study of obesity, body composition, and insulin resistance in 18 women with bipolar disorder and 17 matched control subjects. J Clin Psychiatry. 2008;69:1892\u2013900.","journal-title":"J Clin Psychiatry"},{"key":"158_CR59","first-page":"847","volume":"83","author":"SK Fried","year":"1998","unstructured":"Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83:847\u201350.","journal-title":"J Clin Endocrinol Metab"},{"key":"158_CR60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.atherosclerosis.2006.11.017","volume":"196","author":"S Lim","year":"2008","unstructured":"Lim S, Koo BK, Cho SW, Kihara S, Funahashi T, Cho YM, et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study. Atherosclerosis. 2008;196:398\u2013404.","journal-title":"Atherosclerosis"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0158-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0158-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0158-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:54:23Z","timestamp":1648781663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0158-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,9]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["158"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0158-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,9]]}}}